Multiple Types of Delirium in the ICU Indicate High Risk for Long-Term Cognitive Decline, Study Finds

Article ID: 690009

Released: 23-Feb-2018 9:00 AM EST

Source Newsroom: Health Sciences at the University of Pittsburgh

  • Share

PITTSBURGH, Feb. 26, 2018 – Critically ill patients who experience long periods of hypoxic, septic or sedative-associated delirium, or a combination of the three, during an intensive care unit (ICU) stay are more likely to have long-term cognitive impairment one year after discharge from the hospital, according to a new study from the University of Pittsburgh and Vanderbilt University. This is the first study to show more than half of patients with acute respiratory failure or shock, or both, develop multiple sub-categories of delirium with lasting effects.

The results, published today in the journal Lancet Respiratory Medicine, indicate that clinicians should seek to minimize the duration of exposure of the three delirium groups. 

“Our findings show patients who are exposed to sedative-associated delirium are at similar risk for long-term cognitive impairment as patients exposed to hypoxic or septic delirium,” said lead author Timothy Girard, M.D., M.S.C.I., associate professor of critical care medicine, Pitt School of Medicine. “We were surprised by this because, previously, clinicians believed that sedatives had short-term effects, which were eliminated once the patient regained consciousness. But our results show that clinicians should see it as a red flag when ICU patients respond to sedatives in an adverse manner.”

Sepsis is a condition that arises when the body’s response to an infection injures its own tissues and organs, and hypoxia is a lack of oxygen reaching the body’s tissues. Doctors often sedate ICU patients to help them relax and manage pain. All three conditions—sepsis, hypoxia and sedation—are common during critical illness and can cause delirium.

Delirium was common in the study, affecting 71 percent of participants. Sedative-associated delirium, the most common subcategory, is of particular interest since clinicians control patients’ exposure to sedatives.

Researchers examined more than 1,000 adult medical/surgical patients across five centers with respiratory failure or shock, or both, for hypoxic, septic and sedative-associated delirium, as well as a fourth category, metabolic delirium, which can occur when patients have changes in metabolism due to kidney or liver failure. Researchers assessed 564 patients at a three-month follow-up, and 471 at a one-year follow-up.

The study found duration of delirium as a key indicator of cognitive decline, with longer periods of multiple delirium subcategories predicting worse cognitive decline after one year of hospital discharge.

Out of the four phenotypes, metabolic delirium was the only one that didn’t affect long-term cognitive decline, after adjusting for age, severity of illness, doses of sedating medications and other factors.

“Clinicians should be careful not to underestimate the importance of delirium in sedated patients,” Girard said. “We recommend that clinicians focus on reducing delirium risk factors, including sedation, in addition to treating the critical illness that brought the patient to the ICU.”

Coauthors on this study are Jennifer L. Thompson, M.P.H., Nathan E. Brummel, M.D., Rameela Chandrasekhar, Ph.D., Brenda T. Pun, D.N.P., Leanne M. Boehm, Ph.D., and E. Wesley Ely, M.D., all of Vanderbilt University; Pratik P. Pandharipande, M.D., James C. Jackson, Psy.D., Mayur B. Patel, M.D., Christopher G. Hughes, M.D., Robert S. Dittus, M.D., Vanderbilt University, Mark R. Elstad, M.D., of University of Utah, AND VA Salt Lake City Health Care System; Richard B. Goodman, M.D., University of Washington, VA Puget Sound Health Care System

This research was funded by National Institutes of Health grants AG034257, AG031322, AG027472, AG035117, GM120484, HL111111 and HL135144, and the U.S. Department of Veterans Affairs.

 

 

#  #  #

 

About the University of Pittsburgh School of Medicine

As one of the nation’s leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.

 

Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see www.medschool.pitt.edu.

 

www.upmc.com/media


Comment/Share





Chat now!